Hypera Sa Stock Performance
| HYPMY Stock | USD 3.56 0.09 2.47% |
On a scale of 0 to 100, Hypera SA holds a performance score of 12. The company retains a Market Volatility (i.e., Beta) of 1.4, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Hypera SA will likely underperform. Please check Hypera SA's value at risk, as well as the relationship between the kurtosis and period momentum indicator , to make a quick decision on whether Hypera SA's current trending patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Hypera SA are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile primary indicators, Hypera SA showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 4.7 B | |
| Total Cashflows From Investing Activities | -4.4 B |
Hypera |
Hypera SA Relative Risk vs. Return Landscape
If you would invest 281.00 in Hypera SA on December 19, 2024 and sell it today you would earn a total of 75.00 from holding Hypera SA or generate 26.69% return on investment over 90 days. Hypera SA is currently producing 0.4364% returns and takes up 2.6892% volatility of returns over 90 trading days. Put another way, 23% of traded pink sheets are less volatile than Hypera, and 92% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Hypera SA Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Hypera SA's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Hypera SA, and traders can use it to determine the average amount a Hypera SA's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1623
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | HYPMY | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.69 actual daily | 23 77% of assets are more volatile |
Expected Return
| 0.44 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.16 actual daily | 12 88% of assets perform better |
Based on monthly moving average Hypera SA is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Hypera SA by adding it to a well-diversified portfolio.
Hypera SA Fundamentals Growth
Hypera Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Hypera SA, and Hypera SA fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Hypera Pink Sheet performance.
| Return On Equity | 0.16 | |||
| Return On Asset | 0.0686 | |||
| Profit Margin | 0.23 % | |||
| Operating Margin | 0.33 % | |||
| Current Valuation | 6.39 B | |||
| Shares Outstanding | 631.94 M | |||
| Price To Earning | 19.85 X | |||
| Price To Book | 2.52 X | |||
| Price To Sales | 0.72 X | |||
| Revenue | 5.94 B | |||
| EBITDA | 1.87 B | |||
| Cash And Equivalents | 1.5 B | |||
| Cash Per Share | 2.37 X | |||
| Total Debt | 6.8 B | |||
| Debt To Equity | 0.80 % | |||
| Book Value Per Share | 16.57 X | |||
| Cash Flow From Operations | 1.4 B | |||
| Earnings Per Share | 0.49 X | |||
| Total Asset | 19.82 B | |||
| Retained Earnings | 2.62 B | |||
| Current Asset | 6.68 B | |||
| Current Liabilities | 1.63 B | |||
About Hypera SA Performance
Evaluating Hypera SA's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Hypera SA has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Hypera SA has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypermarcas ADR operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 9000 people.Things to note about Hypera SA performance evaluation
Checking the ongoing alerts about Hypera SA for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Hypera SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Evaluating Hypera SA's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Hypera SA's pink sheet performance include:- Analyzing Hypera SA's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Hypera SA's stock is overvalued or undervalued compared to its peers.
- Examining Hypera SA's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Hypera SA's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Hypera SA's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Hypera SA's pink sheet. These opinions can provide insight into Hypera SA's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Hypera Pink Sheet Analysis
When running Hypera SA's price analysis, check to measure Hypera SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hypera SA is operating at the current time. Most of Hypera SA's value examination focuses on studying past and present price action to predict the probability of Hypera SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hypera SA's price. Additionally, you may evaluate how the addition of Hypera SA to your portfolios can decrease your overall portfolio volatility.